Rigel Pharmaceuticals (RIGL) Tops Q2 EPS by 67c; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.13 -1.49%
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 EPS of $0.88, $0.67 better than the analyst estimate of $0.21. Revenue for the quarter came in at $78.7 million versus the consensus estimate of $54.94 million.
GUIDANCE:
Rigel Pharmaceuticals sees FY2026 revenue of $285-295 million, versus the consensus of $278.9 million.
For earnings history and earnings-related data on Rigel Pharmaceuticals (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AI-powered cyber threats light a fire under cybersecurity stocks
- AMTD Digital reports $1.2B in total assets, $42.4M profit
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
